Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Generic hepatitis C drugs continue to produce high cure rates

Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last

Published
12 hours ago
By
Keith Alcorn
AbbVie combination cures 95% of genotype 3 hepatitis C

AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat,

Published
21 April 2017
By
Keith Alcorn
New AbbVie hepatitis C combination cures 99% of people with cirrhosis

A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12

Published
21 April 2017
By
Keith Alcorn
Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies

People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with

Published
21 April 2017
By
Liz Highleyman
European HCV treatment access survey shows big variations in eligibility

England, Malta, Slovakia, Hungary and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland

Published
20 April 2017
By
Keith Alcorn
Curing hepatitis C reduces cardiovascular risk

Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in

Published
20 April 2017
By
Keith Alcorn
Hepatitis C treatment can be provided successfully at syringe programme sites

Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York

Published
19 April 2017
By
Liz Highleyman
Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

Published
18 April 2017
From
LinkedIn
Hepatitis drug patent application opposed

A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property's Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair competition by precluding the development and distribution of generic versions of Sofosbuvir at lower prices, said a group of 30 activists led by the Aids Access Foundation and Thai Network of People Living with HIV/Aids.

Published
12 April 2017
From
Bangkok Post
WHO prequalifies first generic active ingredient for hepatitis C medicines

On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - India.

Published
05 April 2017
From
World Health Organization
← First12345...89Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.